Role of Wnt/β-catenin signaling in liver metabolism and cancer.

Wnt/β-catenin signaling is known for its role in embryogenesis as well as carcinogenesis. In the liver, it plays many critical roles during hepatic development and regeneration, and its dysregulation is evident in aberrant hepatic growth during various liver tumors. Its chief cellular roles in the liver include regulation of processes of cell proliferation, apoptosis, oxidative stress and differentiation, which in turn contributes to hepatic growth, zonation, xenobiotic metabolism and other metabolic processes inherent to the liver. Most of these functions of the Wnt/β-catenin signaling are dictated through the highly temporal and tissue-specific or non-specific transcriptional targets of the pathway. In addition, some of the critical functions such as cell-cell adhesion and perhaps maintenance of various junctions that are critical from an epithelial cell biology perspective are also a function of β-catenin, which is the central component of the canonical Wnt pathway. Various animal models and clinical studies have demonstrated the spectra of Wnt/β-catenin signaling in liver health and disease. Thus therapeutic modulation of this pathway for improved hepatic health is inevitable in the future. The current review discusses the advances in our understanding of the Wnt/β-catenin signaling in liver physiology and pathology especially in hepatic metabolism and various tumors in adult liver and goes on to extrapolate the pre-clinical significance and possible translational implications of such findings.

[1]  M. Choti,et al.  Hepatic Adenomas: Analysis of Sex Steroid Receptor Status and the Wnt Signaling Pathway , 2002, Modern Pathology.

[2]  Yuh Nung Jan,et al.  PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling , 2001, Nature Cell Biology.

[3]  D. Rickman,et al.  Stabilization of β‐catenin affects mouse embryonic liver growth and hepatoblast fate , 2007, Hepatology.

[4]  S. Kakar,et al.  Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. , 2006, Human pathology.

[5]  D. Rickman,et al.  Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. , 2006, Developmental cell.

[6]  K. Tsuneyama,et al.  Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non‐cirrhotic liver , 2003, Pathology international.

[7]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[8]  A. Kurimasa,et al.  Hepatic differentiation of human bone marrow–derived mesenchymal stem cells by tetracycline‐regulated hepatocyte nuclear factor 3β , 2008, Hepatology.

[9]  M. Romeih,et al.  Alterations of β-catenin and Tcf-4 instead of GSK-3β contribute to activation of Wnt pathway in hepatocellular carcinoma , 2003 .

[10]  G. Michalopoulos,et al.  Beta-catenin is temporally regulated during normal liver development. , 2004, Gastroenterology.

[11]  J. Szatkowski,et al.  Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. , 2003, Cancer letters.

[12]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[13]  Jack A. Taylor,et al.  CTNNB1 mutations and β‐catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1 † , 2001, Molecular carcinogenesis.

[14]  M. Matsuda,et al.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.

[15]  Dianqing Wu,et al.  Protein Phosphatase 2Cα Dephosphorylates Axin and Activates LEF-1-dependent Transcription* , 2000, The Journal of Biological Chemistry.

[16]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[17]  William C. Skarnes,et al.  An LDL-receptor-related protein mediates Wnt signalling in mice , 2000, Nature.

[18]  David I. Smith,et al.  Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.

[19]  E. Yu,et al.  Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. , 2008, Journal of hepatology.

[20]  Y. Jeng,et al.  Expression of mutant nuclear β‐catenin correlates with non‐invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis , 2001, The Journal of pathology.

[21]  Catherine Payne,et al.  Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling , 2008, Proceedings of the National Academy of Sciences.

[22]  William M. Lee,et al.  Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. , 2009, Gastroenterology.

[23]  S. Monga,et al.  Wnt/β-catenin signaling in hepatic organogenesis , 2008 .

[24]  J. Zucman‐Rossi,et al.  Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. , 2008, Journal of hepatology.

[25]  M. Giovannini,et al.  Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Cieply,et al.  Wnt/β‐catenin signaling mediates oval cell response in rodents , 2007 .

[27]  B. Sauer,et al.  Laron Dwarfism and Non-Insulin-Dependent Diabetes Mellitus in the Hnf-1α Knockout Mouse , 1998, Molecular and Cellular Biology.

[28]  K. Basler,et al.  Transcription under the Control of Nuclear Arm/β-Catenin , 2006, Current Biology.

[29]  M. Peifer,et al.  Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. , 2000, Science.

[30]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[31]  S. Sell,et al.  Liver cancer stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Koniaris,et al.  Molecular pathogenesis of hepatocellular carcinoma. , 2006, The Journal of surgical research.

[33]  M. Buendia,et al.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. , 1999, The American journal of pathology.

[34]  Jeremy Nathans,et al.  A new member of the frizzled family from Drosophila functions as a Wingless receptor , 1996, Nature.

[35]  S. Monga,et al.  WNT/β‐catenin signaling in liver health and disease , 2007 .

[36]  J. Zucman‐Rossi,et al.  Over‐expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[37]  S. Feng,et al.  Liver‐specific loss of β‐catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice , 2006, Hepatology.

[38]  B. Cieply,et al.  β‐Catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development , 2008, Hepatology.

[39]  Miran Kim,et al.  Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. , 2004, Gastroenterology.

[40]  B. Cieply,et al.  siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival* , 2007 .

[41]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Stoffel,et al.  Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism , 2001, Nature Genetics.

[43]  G. Michalopoulos,et al.  Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. , 2003, Gastroenterology.

[44]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[45]  J. Qian,et al.  The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. , 2008, Gastroenterology.

[46]  R. Kurek,et al.  Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. , 2002, Cancer research.

[47]  L. Zon,et al.  APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. , 2008, Developmental biology.

[48]  M. Schwarz,et al.  Inducibility of Drug-Metabolizing Enzymes by Xenobiotics in Mice with Liver-Specific Knockout of Ctnnb1 , 2009, Drug Metabolism and Disposition.

[49]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[50]  S. Monga,et al.  R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. , 2007, Journal of hepatology.

[51]  A. Bell,et al.  Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. , 2005, Gastroenterology.

[52]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[53]  Matthias Mann,et al.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.

[54]  R. Nitschke,et al.  Cellular retinol‐binding protein‐1 in hepatocellular carcinoma correlates with β‐catenin, Ki‐67 index, and patient survival , 2003, Hepatology.

[55]  Y. Jeng,et al.  p53 gene and Wnt signaling in benign neoplasms: β‐catenin mutations in hepatic adenoma but not in focal nodular hyperplasia , 2002, Hepatology.

[56]  Jan Bayer,et al.  Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity , 1999, Oncogene.

[57]  W. Thomson,et al.  β-Catenin Signaling: Therapeutic Strategies in Oncology , 2002 .

[58]  R. Moon,et al.  A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. , 1997, Genes & development.

[59]  S. Fan,et al.  β‐catenin mutation and overexpression in hepatocellular carcinoma , 2001 .

[60]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[61]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[62]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[63]  Expression of epithelial cadherin and α‐ and β‐catenins in nontumoral livers and hepatocellular carcinomas , 1996 .

[64]  B. Cieply,et al.  Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. , 2006, Gastroenterology.

[65]  M. Taketo,et al.  Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. , 2002, Cancer research.

[66]  B. Cieply,et al.  beta-Catenin is critical for early postnatal liver growth. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[67]  L. Ellis,et al.  Simplified staging for hepatocellular carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Witte,et al.  The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland , 2009, Journal of cellular physiology.

[69]  I. Hisatome,et al.  A role of Wnt/β-catenin signals in hepatic fate specification of human umbilical cord blood-derived mesenchymal stem cells , 2007 .

[70]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[71]  Mariann Bienz,et al.  LEF-1, a Nuclear Factor Coordinating Signaling Inputs from wingless and decapentaplegic , 1997, Cell.

[72]  Y. Jeng,et al.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. , 2000, The American journal of pathology.

[73]  W. Birchmeier,et al.  Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. , 1998, Science.

[74]  M. Toyota,et al.  Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma , 2008, Journal of Gastroenterology.

[75]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[76]  M. Obata,et al.  Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. , 2003, Carcinogenesis.

[77]  C. Gandhi,et al.  Wnt'er in liver: Expression of Wnt and frizzled genes in mouse , 2007, Hepatology.

[78]  A. Buchmann,et al.  A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. , 2004, Carcinogenesis.

[79]  C. Nguyên,et al.  ICG-001, A Novel Small Molecule Regulator of TCF/β-Catenin Masakatsu Transcription , 2005 .

[80]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[81]  M. Hallek,et al.  Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells , 2009, European journal of haematology.

[82]  S. Hirohashi,et al.  β‐Catenin Accumulation and Mutation of Exon 3 of the β‐Catenin Gene in Hepatocellular Carcinoma , 1999, Japanese journal of cancer research : Gann.

[83]  Walter Birchmeier,et al.  Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. , 2008, Genes & development.

[84]  A. Bell,et al.  Hepatocyte Growth Factor Induces Wnt-independent Nuclear Translocation of β-Catenin after Met-β-Catenin Dissociation in Hepatocytes , 2002 .

[85]  Aarati R. Ranade,et al.  Mouse fetal liver cells in artificial capillary beds in three-dimensional four-compartment bioreactors. , 2005, The American journal of pathology.

[86]  J Mao,et al.  Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt‐mediated regulation of LEF‐1 , 1999, The EMBO journal.

[87]  S. Feng,et al.  Liver‐specific loss of β‐catenin results in delayed hepatocyte proliferation after partial hepatectomy , 2007, Hepatology.

[88]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[89]  R. Krishnan,et al.  GSK-3 phosphorylation and alteration of -catenin in hepatocellular carcinoma , 2003 .

[90]  G. Michalopoulos,et al.  Wnt impacts growth and differentiation in ex vivo liver development. , 2004, Experimental cell research.

[91]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[92]  A. Cadoret,et al.  Hepatomegaly in Transgenic Mice Expressing an Oncogenic Form of β-Catenin , 2001 .

[93]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[94]  H. Ohgaki,et al.  Beta-catenin mutations in liver tumors induced by 2-amino-3,4-dimethylimidazo[4,5-f]quinoline in CDF1 mice. , 2003, Cancer letters.

[95]  D. Carrasco,et al.  Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma , 2007, Proceedings of the National Academy of Sciences.

[96]  Jilly F. Evans,et al.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. , 2003, Cancer research.

[97]  S. Hirohashi,et al.  Overexpression of orphan G‐protein–coupled receptor, Gpr49, in human hepatocellular carcinomas with β‐catenin mutations , 2003, Hepatology.

[98]  L. Neckers,et al.  Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. , 2001, Cancer research.

[99]  A. Tannapfel,et al.  Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis , 2002, Virchows Archiv.

[100]  C. Auffray,et al.  The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. , 2008, Journal of hepatology.

[101]  Lian-tang Wang,et al.  Down-regulation of Wnt signaling could promote bone marrow-derived mesenchymal stem cells to differentiate into hepatocytes. , 2008, Biochemical and biophysical research communications.

[102]  M. Matsuda,et al.  β-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection , 1999 .

[103]  A. McMahon,et al.  Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. , 2001, Development.

[104]  C. Auffray,et al.  HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation* , 2007, Journal of Biological Chemistry.

[105]  O. Sansom,et al.  Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent mechanism. , 2009, Gastroenterology.